{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:43:23Z","timestamp":1791254603139,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Initiative for Innovative Medicine","doi-asserted-by":"crossref","award":["2017-I2M-4-002"],"award-info":[{"award-number":["2017-I2M-4-002"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Initiative for Innovative Medicine","doi-asserted-by":"crossref","award":["2018-I2M-3-001"],"award-info":[{"award-number":["2018-I2M-3-001"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2019PT310026"],"award-info":[{"award-number":["2019PT310026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00259-021-05512-y","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T13:02:54Z","timestamp":1638882174000},"page":"1613-1622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE"],"prefix":"10.1007","volume":"49","author":[{"given":"Wenjia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-083X","authenticated-orcid":false,"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"5512_CR1","first-page":"709","volume":"50","author":"RT Bass","year":"1996","unstructured":"Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, et al. Identification and characterization of novel somatostatin antagonists. Mol Pharmacol. 1996;50:709\u201315.","journal-title":"Mol Pharmacol"},{"key":"5512_CR2","first-page":"502","volume":"47","author":"R Cescato","year":"2006","unstructured":"Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502\u201311.","journal-title":"J Nucl Med"},{"key":"5512_CR3","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","volume":"103","author":"M Ginj","year":"2006","unstructured":"Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436\u201341. https:\/\/doi.org\/10.1073\/pnas.0607761103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5512_CR4","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","volume":"53","author":"M Fani","year":"2012","unstructured":"Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.102764.","journal-title":"J Nucl Med"},{"key":"5512_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.2967\/jnumed.111.087999","volume":"52","author":"M Fani","year":"2011","unstructured":"Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110\u20138. https:\/\/doi.org\/10.2967\/jnumed.111.087999.","journal-title":"J Nucl Med"},{"key":"5512_CR6","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1021\/jm701618q","volume":"51","author":"R Cescato","year":"2008","unstructured":"Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem. 2008;51:4030\u20137. https:\/\/doi.org\/10.1021\/jm701618q.","journal-title":"J Med Chem"},{"key":"5512_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2967\/jnumed.115.167007","volume":"57","author":"SU Dalm","year":"2016","unstructured":"Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med. 2016;57:260\u20135. https:\/\/doi.org\/10.2967\/jnumed.115.167007.","journal-title":"J Nucl Med"},{"key":"5512_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"D Wild","year":"2014","unstructured":"Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248\u201352. https:\/\/doi.org\/10.2967\/jnumed.114.138834.","journal-title":"J Nucl Med"},{"key":"5512_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59:915\u201321. https:\/\/doi.org\/10.2967\/jnumed.117.199760.","journal-title":"J Nucl Med"},{"key":"5512_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.119.235093","volume":"61","author":"W Zhu","year":"2020","unstructured":"Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. Head-to-head comparison of (68)Ga-DOTA-JR11 and (68)Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61:897\u2013903. https:\/\/doi.org\/10.2967\/jnumed.119.235093.","journal-title":"J Nucl Med"},{"key":"5512_CR11","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1097\/rlu.0000000000002906","volume":"45","author":"J Zhang","year":"2020","unstructured":"Zhang J, Kulkarni HR, Singh A, Baum RP. Successful intra-arterial peptide receptor radionuclide therapy of DOTATOC-negative high-grade liver metastases of a pancreatic neuroendocrine neoplasm using 177Lu-DOTA-LM3. Clin Nucl Med. 2020;45:e165\u20138. https:\/\/doi.org\/10.1097\/rlu.0000000000002906.","journal-title":"Clin Nucl Med"},{"key":"5512_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/RLU.0000000000003262","volume":"45","author":"W Zhu","year":"2020","unstructured":"Zhu W, Cheng Y, Ding N, Huo L. Extensive tumor thrombosis of portal venous system demonstrated on 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET\/CT in a patient with well-differentiated neuroendocrine tumor. Clin Nucl Med. 2020;45:902\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000003262.","journal-title":"Clin Nucl Med"},{"key":"5512_CR13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.253096","author":"L Huo","year":"2021","unstructured":"Huo L, Zhu W, Cheng Y, Jia R, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the safety, biodistribution, and dosimetry of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.253096.","journal-title":"J Nucl Med"},{"key":"5512_CR14","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58:61S-S66. https:\/\/doi.org\/10.2967\/jnumed.116.186783.","journal-title":"J Nucl Med"},{"key":"5512_CR15","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.2967\/jnumed.111.088922","volume":"52","author":"D Wild","year":"2011","unstructured":"Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412\u20137. https:\/\/doi.org\/10.2967\/jnumed.111.088922.","journal-title":"J Nucl Med"},{"key":"5512_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.113.126177","volume":"55","author":"I Velikyan","year":"2014","unstructured":"Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204\u201310. https:\/\/doi.org\/10.2967\/jnumed.113.126177.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05512-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05512-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05512-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:08:08Z","timestamp":1647947288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05512-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5512"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05512-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"The data has already been published on ENETS 2021\u201418th Annual Conference and awarded Best Poster prize.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication."}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}